Jazz Pharmaceuticals Completes Sale of its Women's Health Business to Meda For $95M
Jazz Pharmaceuticals (NASDAQ: JAZZ) today announced the closing of the sale of its women's health business to Meda (an international specialty pharmaceutical company) for $95 million in cash.
The products included in the sale are Elestrin® (estradiol gel), Gastrocrom® (cromolyn sodium, USP), Natelle® One (prenatal vitamin), AVC™ Cream (sulfanilamide), Gesticare® DHA (prenatal multi-vitamin) and Urelle® (urinary antiseptic).
For accounting purposes, the women's health business will be treated as a discontinued operation. More detail about the accounting impact of the transaction will be disclosed in pro forma financial statements filed on a Form 8-K and in the company's Form 10-Q for the quarter ended September 30, 2012.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.